ScarTec Therapeutics is a biotech company developing novel therapeutics against clinical indications with unmet clinical needs, mainly focused on fibrosis and tumor stroma. ScarTec Therapeutics (‘ScarTec’) was spun-out in 2017 by the University of Twente by the research group of Prof. Jai Prakash. Its mission is to develop novel, targeted, peptide-based drugs to treat pancreatic cancer and other fibrosis-associated cancers as well as fibrotic diseases with high unmet medical needs. ScarTec’s core focus is around the preclinical and early clinical development of our candidates.
Our novel and breakthrough lead candidates reduce fibrotic stroma, to enhance the efficacy of existing and emerging therapies for cancers with the poorest survival rates. The lead indication for ScarTec is pancreatic cancer, but proprietary platform offers broad opportunities against other solid cancers and fibrotic diseases.
